The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchFever with shaking chills.
How PNC-27 works
Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain — researched for selectively forming pores in cancer-cell membranes while sparing normal cells.
PNC-27 is two peptides stitched end to end, and the whole molecule only makes sense once you know which half does what. The front half is residues 12–26 of human p53 — the stretch of the p53 transactivation domain that binds HDM-2, the human double minute 2 protein.
The mechanism is not the one the name suggests. HDM-2 is famous as the ubiquitin ligase that degrades p53, and the obvious guess is that a p53 fragment blocks that interaction and restores p53. That is not what this peptide does.
- Injectable
Research on PNC-276 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: In-vitro + animal (oncology research).
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
This is the compound in the Vault most likely to be encountered by someone who is frightened and looking for options, and the honest position needs stating plainly: there are no human trials, and no clinical evidence of benefit in any cancer.
It is sold in the research market with claims that outrun the data by a wide margin. Choosing it over evaluated oncology care is where the real harm sits.
How the mechanism reads
A peptide combining a p53 fragment with a membrane-penetrating sequence. Cell work reports it binds HDM-2 in the membranes of cancer cells and forms pores, causing necrosis — while sparing normal cells, which are said to express far less membrane HDM-2.
MechanisticThe selectivity claim is the entire premise and it rests on cell culture. Selectivity that holds in a dish routinely fails in a body, where distribution, protein binding and clearance all intervene.
Experimental, animal or cellA pore-forming mechanism predicts its own risk: if the selectivity is imperfect in vivo, the damage is membrane lysis in whatever tissue it reaches.
Mechanistic
Sources
- Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences 2010 · PMID 20080680
- Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines 2022 · PMID 35625682
- Krzesaj P, et al. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical and Laboratory Science 2024 · PMID 38802154
- Pincus MR, et al. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines 2024 · PMID 38927351
- Thadi A, et al. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes. Annals of Clinical and Laboratory Science 2020 · PMID 33067207
- Davitt K, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science 2014 · PMID 25117093
PNC-27 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- A cancer diagnosis in which you plan to use it in place of established treatment.
- Kidney or liver failure: pore-forming activity against membranes in organs that clear drugs is untested.
- Needing an unsterile or unverified source for an intravenous route.
- Pregnancy: membrane-disrupting peptides carry no safety data.
- Active infection or immune suppression.
What’s expected
- Human effects are unknown; evidence is test-tube and animal only.
- Fever, chills or fatigue if it provokes an immune or lytic reaction.
- Local soreness where it is applied.
Watch for
- Fever with shaking chills.
- Hives, throat tightness or low blood pressure.
- Passing little or dark urine.
- Unexplained bleeding or bruising.
Labs that tell you it’s working
- Complete Blood Count (CBC) w/ Differential
- Comprehensive Metabolic Panel (CMP)
- Cystatin C with eGFR
- hs-CRP (C-Reactive Protein, High Sensitivity)
A p53 HDM-2 binding domain joined to a membrane-pore domain, researched for pores in cancer cells; no human results. PMID 20080680 PMID 25117093
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
PNC-27 FAQ4 common questions
- Is PNC-27 approved for human use?
- No. PNC-27 is a research compound. No completed randomized human trial has given it yet.
- What is PNC-27 researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Complete Blood Count; Comprehensive Metabolic Panel; Cystatin C with eGFR; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for PNC-27: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



